Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01244503 · ClinicalTrials.gov registry record · Phase 2
Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT01244503 is a Phase 2 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 61 participants.
The verdict
NCT01244503, a Phase 2 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of the study is to demonstrate that the ¹³C-Octanoate Breath Test (OBT) can be used as an aid, in conjunction with other clinical information and medical history, for evaluating disease severity and detecting NASH with a high probability.
Interventions
- DRUG Sodium Octanoate Breath Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01244503
The ClinicalTrials.gov registry entry for NCT01244503 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sodium Octanoate Breath Test is the first listed.
NCT01244503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01244503 about?
NCT01244503 is a clinical study titled "Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)". The purpose of the study is to demonstrate that the ¹³C-Octanoate Breath Test (OBT) can be used as an aid, in conjunction with other clinical information and medical history, for evaluating disease severity and detecting NASH with a high probability.
What is the current status of trial NCT01244503?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2011-02. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01244503?
The interventions under investigation include: Sodium Octanoate Breath Test (DRUG).
Who is sponsoring clinical trial NCT01244503?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.